February 7, 2014
A New Tide Approaches
Simeprevir and sofosbuvir both represent a further step in the evolution of more effective, less-toxic HCV treatment options. But they, too, are just the beginning. Numerous direct-acting antiretrovirals are currently moving through the latter stage of the development pipeline, suggesting that the treatment landscape by early 2015 may look as different from the present as the present does from just a few years earlier.
For the notoriously hard-to-treat HCV genotype 1 in particular, Cox states: "It's hard to predict, but right now in advanced testing, there are some combinations that are inteferon-sparing" yet have very high sustained virologic response rates -- and may not even require the use of ribavirin.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|Which HIV Treatment Regimen to Start With in 2015|
|Five Promising HIV Drugs in the Pipeline|
|What's Hot in HIV Clinical Science|
|This Week in HIV Research: Editing Human CD4 Cells; Effect of Treatment on Artery Wall Thickness; Universal Treatment; and More|
|The Most Important HIV Study at IDWeek 2015|
|Health Outcomes Worse for HIV-Positive Black Men Even Despite Equal Access|